MAPT and Alzheimer disease: Nonetheless, clinical trials involving both healthy individuals and those with mild cognitive impairment or AD are warranted to investigate whether melatonin can enhance the glymphatic system’s efficacy in reducing brain concentrations of Aβ and tau.